Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Jan. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune,...

Hence then, the article about innovent dosed first participant in phase 3 clinical study glory 2 of mazdutide ibi362 higher dose 9 mg in chinese adults with obesity was published today ( Tuesday 02/01/2024 - 03:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity )

Also on site :

• XPENG-Peking University Collaborative Research Accepted by AAAI 2026: Introducing a Novel Visual Token Pruning Framework for Autonomous Driving
• John Legend Celebrates 47th Birthday With Family Slime Outing in New York
• Kurtenbach: These unbelievable 49ers might just be a team of destiny